Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease.

Dengue virus (DENV) encodes a unique protease (NS3/NS2B) essential for its maturation and infectivity and, it has become a key target for anti-viral drug design to treat dengue and other flavivirus related infections. Present investigation established that some of the drug molecules currently used m...

Full description

Bibliographic Details
Main Authors: R V Sriram Uday, Rajdip Misra, Annaram Harika, Sandip Dolui, Achintya Saha, Uttam Pal, V Ravichandiran, Nakul C Maiti
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0257206
_version_ 1818436196164960256
author R V Sriram Uday
Rajdip Misra
Annaram Harika
Sandip Dolui
Achintya Saha
Uttam Pal
V Ravichandiran
Nakul C Maiti
author_facet R V Sriram Uday
Rajdip Misra
Annaram Harika
Sandip Dolui
Achintya Saha
Uttam Pal
V Ravichandiran
Nakul C Maiti
author_sort R V Sriram Uday
collection DOAJ
description Dengue virus (DENV) encodes a unique protease (NS3/NS2B) essential for its maturation and infectivity and, it has become a key target for anti-viral drug design to treat dengue and other flavivirus related infections. Present investigation established that some of the drug molecules currently used mainly in cancer treatment are susceptible to bind non-active site (allosteric site/ cavity) of the NS3 protease enzyme of dengue virus. Computational screening and molecular docking analysis found that dabrafenib, idelalisib and nintedanib can bind at the allosteric site of the enzyme. The binding of the molecules to the allosteric site found to be stabilized via pi-cation and hydrophobic interactions, hydrogen-bond formation and π-stacking interaction with the molecules. Several interacting residues of the enzyme were common in all the five serotypes. However, the interaction/stabilizing forces were not uniformly distributed; the π-stacking was dominated with DENV3 proteases, whereas, a charged/ionic interaction was the major force behind interaction with DENV2 type proteases. In the allosteric cavity of protease from DENV1, the residues Lys73, Lys74, Thr118, Glu120, Val123, Asn152 and Ala164 were involved in active interaction with the three molecules (dabrafenib, idelalisib and nintedanib). Molecular dynamics (MD) analysis further revealed that the molecules on binding to NS3 protease caused significant changes in structural fluctuation and gained enhanced stability. Most importantly, the binding of the molecules effectively perturbed the protein conformation. These changes in the protein conformation and dynamics could generate allosteric modulation and thus may attenuate/alter the NS3 protease functionality and mobility at the active site. Experimental studies may strengthen the notion whether the binding reduce/enhance the catalytic activity of the enzyme, however, it is beyond the scope of this study.
first_indexed 2024-12-14T17:04:56Z
format Article
id doaj.art-5cdadd6cff564a66ac6bfef33c321c75
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-14T17:04:56Z
publishDate 2021-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-5cdadd6cff564a66ac6bfef33c321c752022-12-21T22:53:44ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01169e025720610.1371/journal.pone.0257206Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease.R V Sriram UdayRajdip MisraAnnaram HarikaSandip DoluiAchintya SahaUttam PalV RavichandiranNakul C MaitiDengue virus (DENV) encodes a unique protease (NS3/NS2B) essential for its maturation and infectivity and, it has become a key target for anti-viral drug design to treat dengue and other flavivirus related infections. Present investigation established that some of the drug molecules currently used mainly in cancer treatment are susceptible to bind non-active site (allosteric site/ cavity) of the NS3 protease enzyme of dengue virus. Computational screening and molecular docking analysis found that dabrafenib, idelalisib and nintedanib can bind at the allosteric site of the enzyme. The binding of the molecules to the allosteric site found to be stabilized via pi-cation and hydrophobic interactions, hydrogen-bond formation and π-stacking interaction with the molecules. Several interacting residues of the enzyme were common in all the five serotypes. However, the interaction/stabilizing forces were not uniformly distributed; the π-stacking was dominated with DENV3 proteases, whereas, a charged/ionic interaction was the major force behind interaction with DENV2 type proteases. In the allosteric cavity of protease from DENV1, the residues Lys73, Lys74, Thr118, Glu120, Val123, Asn152 and Ala164 were involved in active interaction with the three molecules (dabrafenib, idelalisib and nintedanib). Molecular dynamics (MD) analysis further revealed that the molecules on binding to NS3 protease caused significant changes in structural fluctuation and gained enhanced stability. Most importantly, the binding of the molecules effectively perturbed the protein conformation. These changes in the protein conformation and dynamics could generate allosteric modulation and thus may attenuate/alter the NS3 protease functionality and mobility at the active site. Experimental studies may strengthen the notion whether the binding reduce/enhance the catalytic activity of the enzyme, however, it is beyond the scope of this study.https://doi.org/10.1371/journal.pone.0257206
spellingShingle R V Sriram Uday
Rajdip Misra
Annaram Harika
Sandip Dolui
Achintya Saha
Uttam Pal
V Ravichandiran
Nakul C Maiti
Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease.
PLoS ONE
title Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease.
title_full Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease.
title_fullStr Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease.
title_full_unstemmed Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease.
title_short Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease.
title_sort dabrafenib idelalisib and nintedanib act as significant allosteric modulator for dengue ns3 protease
url https://doi.org/10.1371/journal.pone.0257206
work_keys_str_mv AT rvsriramuday dabrafenibidelalisibandnintedanibactassignificantallostericmodulatorfordenguens3protease
AT rajdipmisra dabrafenibidelalisibandnintedanibactassignificantallostericmodulatorfordenguens3protease
AT annaramharika dabrafenibidelalisibandnintedanibactassignificantallostericmodulatorfordenguens3protease
AT sandipdolui dabrafenibidelalisibandnintedanibactassignificantallostericmodulatorfordenguens3protease
AT achintyasaha dabrafenibidelalisibandnintedanibactassignificantallostericmodulatorfordenguens3protease
AT uttampal dabrafenibidelalisibandnintedanibactassignificantallostericmodulatorfordenguens3protease
AT vravichandiran dabrafenibidelalisibandnintedanibactassignificantallostericmodulatorfordenguens3protease
AT nakulcmaiti dabrafenibidelalisibandnintedanibactassignificantallostericmodulatorfordenguens3protease